

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n. 1 posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale 11/E3, settore scientifico-disciplinare Psicologi a Sociale, del Lavoro e delle Organizzazioni, ssd M-PSI/05 - Psicologia Sociale presso il Dipartimento di Oncologia ed Emato-Oncologia, (avviso bando pubblicato sulla G.U. n. 18 del 05/03/2019) Codice concorso 4027

[Nicola Orofino] **CURRICULUM VITAE**

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	OROFINO
NOME	NICOLA
DATA DI NASCITA	[06/09/1982

INSERIRE IL PROPRIO CURRICULUM
(non eccedente le 30 pagine)

CURRICULUM VITAE



INFORMAZIONI PERSONALI

Nome OROFINO, NICOLA

Indirizzo Viale Assunta, 37 - 20063, Cernusco sul Naviglio (Milano)

Telefono 3485279160

Fax

E-mail orofino.nic@gmail.com

Nazionalità Italiana

Data di nascita 06/09/1982

ESPERIENZA LAVORATIVA

- Date (da – a) **01 Gennaio 2019 - presente**
- Nome e indirizzo del datore di lavoro ASST Melegnano e Martesana
PO Cernusco sul Naviglio, UOC Oncologia Medica
- Principali mansioni e responsabilità Dirigente Medico di I livello

- Date (da – a) **01 Gennaio 2016 - 31 Dicembre 2018**
- Nome e indirizzo del datore di lavoro Fondazione IRCCS Ospedale Maggiore Policlinico, Milano
UOC Oncoematologia
- Principali mansioni e responsabilità Incarico di collaborazione coordinata e continuativa:
“Coordinamento dell’attività diagnostica nell’ambito del centro DEmA (Diagnostica Ematologica dell’Anziano) ed attività clinica e di ricerca all’interno della UOC di Oncoematologia”

- Date (da – a) **01 Gennaio 2015 - 31 Dicembre 2015**
- Nome e indirizzo del datore di lavoro Fondazione IRCCS Ospedale Maggiore Policlinico, Milano
UOC Oncoematologia
- Principali mansioni e responsabilità Incarico di collaborazione coordinata e continuativa:
“HEMINSIGHT: una modalità innovativa per migliorare la qualità di vita (QoL) dei pazienti affetti da leucemia linfatica cronica (LLC)”

- Date (da – a) **01 Agosto 2014 – 31 Dicembre 2014**
- Nome e indirizzo del datore di lavoro Fondazione IRCCS Ospedale Maggiore Policlinico, Milano
UOC Oncoematologia
- Principali mansioni e responsabilità Incarico di collaborazione coordinata e continuativa: “Gestione clinica di studi interventistici ed osservazionali relativi alla Leucemia Linfatica cronica (LLC) e alle Malattie Mieloproliferative”

- Date (da – a) **Luglio 2009 - Luglio 2014**
- Nome e indirizzo del datore di lavoro Università degli studi di Milano
- Principali mansioni e responsabilità Medico Specializzando in Ematologia c/o UO Oncoematologia
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milano
Gestione clinica pazienti affetti da malattie oncoematologiche
Gestione studi clinici in GCP nella leucemia linfatica cronica e nelle Neoplasie Mieloproliferative (LMC e MPNs)
Attività di ricerca clinica

ALTRE ESPERIENZE

Coinvolgimento come co-investigatore nei seguenti studi clinici investigator-initiated e company-sponsored, condotti in accordo con le linee guida ICH-GCP (studi di fase II-III ed osservazionali):

- A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID
- Randomized, open label, multicenter phase IIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with Polycythemia Vera who are hydroxyurea resistant or intolerant (RESPONSE-2)
- A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib
- A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlorambucil in Combination with Obinutuzumab in Subjects with Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
- A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL)
- A Phase 3, Multicenter, Randomized, Doubleblind Study to Compare the Efficacy and Safety of oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes
- A Phase 3, Multicenter, Randomized, Open Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia

- A randomized, double blind, placebo-controlled, multicenter, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations
- Phase 2 multicenter, study to assess the efficacy and the safety of front-line Fludarabine, Cyclophosphamide and Ofatumumab (FCO2) chemoimmunotherapy in young (≤ 65 yrs) patients with Chronic Lymphocytic Leukemia (CLL)
- Optimizing Ponatinib Use (OPUS). A GIMEMA phase 2 study of the activity and risk profile of ponatinib, 30 mg once daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) patients resistant to imatinib
- A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera
- Long-term study evaluating the effect of Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
- The benefit/risk profile of Pegylated proline-Interferon alpha-2b (AOP2014) added to the best available strategy based on phlebotomies in low-risk patients with Polycythemia Vera (PV) The Low-PV randomized trial
- A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
- An International Multi-Centric Observational Study on the Use of Ruxolitinib in the Treatment of Patients with Polycythemia Vera resistant or intolerant to hydroxyurea
- A phase 3, randomized, open-label, active-controlled study of ALXN1210 versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) currently treated with eculizumab
- Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response

- Studying interventions for managing patients with CML in chronic phase: the 5-year prospective cohort study (Simplicity)
- Bosutinib efficacy safety tolerability (BEST) study in elderly chronic myeloid leukemia patients failing front-line treatment with other tyrosine kinase inhibitors
- Novel strategies of antithrombotic prophylaxis in patients with essential thrombocythemia: comparison of different dosing regimens of administration of low-dose acetylsalicylic acid
- Next-Generation Sequencing for BCR-ABL KD Mutation Screening in Philadelphia Chromosome-Positive Leukemias

ISTRUZIONE E FORMAZIONE

- Data 08/07/2014
Università degli Studi di Milano Diploma di Specializzazione in Ematologia con votazione 70/70 e lode. Tesi discussa: ***“Sindromi Ipereosinofile: mutazioni puntiformi e loro ruolo nella risposta alla terapia con inibitori delle tirosin-chinasi”***
- Data Aprile 2008
Università degli Studi di Milano Diploma di abilitazione all’esercizio della Professione medica
- Data 30/10/2007
Università degli Studi di Milano Laurea Magistrale in Medicina e Chirurgia con votazione 110/110 e lode. Tesi discussa: ***“Leucemia linfoblastica Ph’-positiva. Esperienze policentriche sull’utilizzo di chemioterapia ed inibitori delle tirosin-chinasi”***
- Data Anno scolastico 2000-2001
Liceo Scientifico “G. De Lorenzo” – Lagonegro (PZ) Diploma di Maturità Scientifica

CAPACITÀ E COMPETENZE PERSONALI.

MADRELINGUA ITALIANA

ALTRE LINGUE

- INGLESE
- Capacità di lettura BUONO
- Capacità di scrittura BUONO
- Capacità di espressione orale BUONO

FRANCESE

Diplome d'Etudes en Langue Française I (DELF I) du Ministère dell'Education Nationale de la Republique Française.

- Capacità di lettura BUONO
- Capacità di scrittura BUONO
- Capacità di espressione orale BUONO

CAPACITÀ E COMPETENZE OTTIME CAPACITÀ INFORMATICHE CON UTILIZZO DI MACINTOSH
TECNICHE WINDOWS, PACCHETTO OFFICE, E SOFTWARE STATISTICI (SPSS,
. GRAPHPAD PRISM)

PATENTE O PATENTI Patente di guida B

ELENCO PUBBLICAZIONI

- **Lymphocytic variant hypereosinophilia: a challenging diagnosis of a rare disease with pleomorphic clinical picture.**

Orofino N, Mattiello V, Schinco GL, Gianelli U, Iurlo A. *Eur J Intern Med*. 2018 Aug 9. pii: S0953-6205(18)30321-2. doi: 10.1016/j.ejim.2018.08.004. [Epub ahead of print]

- **Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients**

Mario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, Alessandra Iurlo, Francesca Cibien, Elena Maino, Anna Guella, Gianluca Festini, Claudia Minotto, Ercole De Biasi, Federico De Marchi, Luigi Scaffidi, Luca Frison, Cristina Bucelli, Marta Medeot, Elisabetta Calistri, Rosaria Sancetta, Manuela Stulle, Nicola Orofino, Mauro Krampera, Filippo Gherlinzoni, Gianpietro Semenzato, Giovanni Pizzolo, Achille Ambrosetti, Renato Fanin. *Oncotarget*. 2018 Feb 12;9(18):14219-14227

- **Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.**

Iurlo A, Cattaneo D, Orofino N, Bucelli C, Molica M, Breccia M. *Clin Drug Investig*. 2018 Jan 23. doi: 10.1007/s40261-018-0623-7.

- **Clinical Management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda – Lombardy Hematologic Network, Italy)**

Fracchiolla N, Todisco E, Bilancia A, Gandolfi S, Orofino N, Guidotti F, Mancini V, Marbello L, Assanelli A, Bernardi M, Santoro A, Cairoli R, Consonni D, Cortelezzi A. *Am J Hematol*. 2017 Dec;92(12):E656-E659. doi: 10.1002/ajh.24903. Epub 2017 Oct 10

- **Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia**

Alessandra Iurlo, Cristina Bucelli, Daniele Cattaneo, Nicola Orofino, Juri Alessandro Giannotta, Manuela Zappa, Umberto Giannelli, Agostino Cortelezzi. *Ann Hematol*. Accepted 11 August 2017

- **An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review**

Nicola Orofino, Daniele Cattaneo, Cristina Bucelli, Loredana Pettine, Sonia Fabris, Umberto Gianelli, Nicola Stefano Fracchiolla, Agostino Cortelezzi, Alessandra Iurlo. *Leukemia Research Reports* 8 (2017) 7–10. Accepted 25 July 2017

- **Prognostic significance of a comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients**

Gianelli U, Fiori S, Cattaneo D, Bossi A, Cortinovis I, Bonometti A, Ercoli G, Bucelli C, Orofino N, Bulfamante G, Iurlo A. *Histopathology*. 2017 Jul 15. doi: 10.1111/his.13309. [epub ahead of print]

- **Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report.**

Reda G, Fattizzo B, Cassin R, Flospergher E, Orofino N, Gianelli U, Barcellini W, Cortelezzi A. *Oncol Lett*. 2017 Mar; 13(3): 1307-1310

- **Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers**

Sciumè M, Mattiello V, Cattaneo D, Bucelli C, Orofino N, Gandolfi L, Pettine L, Lonati S, Gianelli U, Pierini A, Cortelezzi A, Iurlo A. *Am J Hematol*. 2017 Apr;92(4): E47-E48.

- **The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.**

Gianelli U, Cattaneo D, Bossi A, Cortinovis I, Boiocchi L, Liu YC, Augello C, Bonometti A, Fiori S, Orofino N, Guidotti F, Orazi A, Iurlo A. *Mod Pathol*. 2017 Feb; 30(2): 169-179.

- **Biological and molecular characterization of a rare case of cutaneous Richter syndrome.**

Reda G, Cassin R, Fabris S, Ciceri G, Fattizzo B, Sciumè M, Orofino N, Gianelli U, Neri A, Cortelezzi A. *Hematol Oncol*. 2016 Jul 12. doi: 10.1002/hon.2327.

- **Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera: A Case Report.**

Iurlo A, Dagna L, Cattaneo D, Orofino N, Bianchi P, Cavalli G, Doglioni C, Gianelli U, Cortelezzi A. *Medicine (Baltimore)*. 2016 May;95(20):e3697.

- **Anagrelide and Mutational Status in Essential Thrombocythemia.**

Iurlo A, Cattaneo D, Orofino N, Bucelli C, Fabris S, Cortelezzi A. *BioDrugs*. 2016 Jun;30(3):219-23.

- **Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma.**

Orofino N, Guidotti F, Cattaneo D, Sciumè M, Gianelli U, Cortelezzi A, Iurlo A. *Leuk Lymphoma*. 2016 Mar 17:1-4.

- **Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.**

Reda G, Orofino N, Cassin R, Sciumè M, Fattizzo B, Cortelezzi A. *Expert Opin Drug Saf*. 2016 Jun;15(6):865-73.

- **Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?**

Iurlo A, Orsi E, Cattaneo D, Resi V, Bucelli C, Orofino N, Sciumè M, Elena C, Grancini V, Consonni D, Orlandi EM, Cortelezzi A. *Oncotarget*. 2015 Sep 10.

- **Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.**

Sciumè M, Vincenti D, Reda G, Orofino N, Cassin R, Giannarelli D, Gaidano G, Rossi D, Cortelezzi A. *Am J Hematol*. 2015 Jul 22.

- **Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.**

Iurlo A, Cattaneo D, Boiocchi L, Orofino N, Fermo E, Cortelezzi A, Gianelli U. *Ann Hematol*. 2015 Oct;94(10):1749-51.

- **Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre.**

Iurlo A, Cattaneo D, Giunta M, Gianelli U, Consonni D, Fraquelli M, Orofino N, Bucelli C, Bianchi P, Augello C, Bosari S, Colombo M, Cortelezzi A. *Br J Haematol*. 2015 Sep;170(6):890-2.

- **A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.**

Cassinerio E, Roghi A, Orofino N, Pedrotti P, Zanaboni L, Poggiali E, Giuditta M, Consonni D, Cappellini MD. *Ann Hematol*. 2015 Jun;94(6):939-45.

- **Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.**

Iurlo A, Gianelli U, Beghini A, Spinelli O, Orofino N, Lazzaroni F, Cambiaghi S, Intermesoli T, Rambaldi A, Cortelezzi A. *Oncotarget*. 2014 Jul 15;5(13):4665-70.

- **Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.**

Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD. *Blood Cells Mol Dis*. 2014 Sep;53(3):164-7.

- **Choosing treatment options for patients with relapsed/refractory multiple myeloma.**

Castelli R, Orofino N, Losurdo A, Gualtierotti R, Cugno M. *Expert Rev Anticancer Ther*. 2014 Feb;14(2):199-215.

- **Current and emerging treatment options for patients with relapsed myeloma.**

Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, Cugno M. *Clin Med Insights Oncol*. 2013 Aug 19;7:209-19.

- **Unilateral exophthalmos and multiple subcutaneous nodules as a result of extranodal marginal zone lymphoma.**

Vincenti D, Orofino N, Ferrario A, Goldaniga M, Rossi F, Olivero B, Baldini L. *J Clin Oncol*. 2012 Feb 20;30(6):e69-73.

ELENCO PUBBLICAZIONI

Abstract e comunicazioni orali a congressi

Meeting of the Peripheral Nerve Society July 4-8, 2009 Würzburg, Germany

Acute idiopathic polyneuropathy after subcutaneous alemtuzumab (al) therapy in chronic lymphocytic leukemia (cll) patients

Reda G, Castelli R, Aprile von Hohenstaufen K, **Orofino N**, Conti G, Cortelezzi A, Bresolin N

42° Congresso Nazionale Società Italiana di Ematologia, Milano 18-21 ottobre 2009

Ematopoiesi inefficace e marcatori di angiogenesi nelle sindromi mielodisplastiche

Cortelezzi A., Gritti G., Lonati S., Silvestris I., **Orofino N.**, Aprile K., Reda G., Freyrie A., Lambertenghi Delilieri G. (Milano)

51st ASH annual meeting and exposition, New Orleans, LA december, 5-8, 2009

Relationship Between Expression of TLRs and Disease Activity in CLL.

Wilma Barcellini, Anna Zaninoni, Francesca Guida Imperiali, Gianluigi Reda, **Nicola Orofino**, Agostino Cortelezzi, and Alberto Zanella

43° Congresso Nazionale Società Italiana di Ematologia, Napoli 16-19 ottobre 2011

Studio retrospettivo relativo agli schemi di chemioterapia di salvataggio nel linfoma di Hodgkin recidivato o refrattario

Vincenti D., Ferrario A., **Orofino N.**, Goldaniga M., Rossi F., Annaloro C., Tagliaferri E., Onida F., Olivero B., Baldini L.

Ruolo della PET nei linfomi indolenti

Rossi F., Ferrario A., Olivero B., Goldaniga M., Vincenti D., **Orofino N.**, Castellani M., Gerundini P., Baldini L. (Milano)

16th Congress of the European Hematology Association, London, United Kingdom, June 9-12, 2011

Post-transplant lymphoproliferative disorders in liver and kidney recipients: a single institution experience

A Ferrario, D Vincenti, F Rossi, **N Orofino**, B Olivero, M Goldaniga, L Cro, L Baldini

53rd ASH Annual Meeting and Exposition, San Diego, CA, December, 10-13, 2011

A Retrospective Analysis of Mantle Cell Lymphoma Patients Series Treated Upfront by Sequential High Dose Immunochemotherapy Supported by In Vivo Purged Stem Cell Double Autologous Transplantation: A Monocentric Experience

Andrea Ferrario, Giorgia Saporiti, **Nicola Orofino**, Francesco Onida, Daniele Vincenti, Claudia Basilico, Francesca Gaia Rossi, Barbara Olivero, Maria Cecilia Goldaniga, Elena Tagliaferri, Claudio Annaloro, and Luca Baldini
Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 4949.

54th ASH Annual Meeting and Exposition, Atlanta, GA, December, 2012

Immune Thrombocytopenia Associated to Low-Dose Alemtuzumab Therapy in Chronic Lymphocytic Leukemia: A Single Retrospective Center Experience

Gianluigi Reda, Francesco Maura, Giuseppe Gritti, Daniele Vincenti, Mariarita Sciumé, **Nicola Orofino**, Anna Ines Gregorini, Cristina Bucelli, Francesca Inda, Francesca Guidotti, Alfonso Piciocchi, Francesco Rodeghiero, Antonino Neri and Agostino Cortelezzi

18th Congress of the European Hematology Association, Stockholm, Sweden, June 2013

Combination of Deferasirox and Deferoxamine in clinical practice: alternative schemes of chelation in Thalassemia Major (TM) patients

E. Cassinerio, L. Zanaboni, A. Roghi, E. Poggiali, I. Gandolfi, M. Mazzoleni, L. Duca, **N. Orofino**, M. Cappellini

12th International Symposium on Myelodysplastic Syndromes Berlin, Germany, 2013

Recombinant human erythropoietin improves quality of life and brain function in elderly patients with low-risk myelodysplastic syndromes

R. Castelli, C. Arici, **N. Orofino**, G. Moreo, L. Gatti, G. Schinco, M. Cugno.

Results of 5-azacitidine therapy in patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

A. Freyrie, G. Reda, D. Vincenti, V. Ferla, **N. Orofino**, M. Sciumè, F. Guidotti, A. Cortelezzi

19th Congress of the European Hematology Association, Milan, Italy, June 2014

A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS OF ANTIFUNGAL TREATMENTS IN ONCO-HEMATOLOGIC PATIENTS

N. S. Fracchiolla, F. Guidotti, **N. Orofino**, A. Cortelezzi

ACUTE MYELOID LEUKEMIA IN PREGNANCY: A SINGLE CENTRE EXPERIENCE

Fracchiolla, F. Guidotti, F. D'Ambrosi, **N. Orofino**, C. Boschetti, M. Colombi, M. W. Ossola, L. Napolitano, A. Cortelezzi

ADDITIONAL CHROMOSOMAL ABNORMALITIES IN ACUTE PROMYELOCYTIC LEUKEMIA: A SINGLE-INSTITUTION EXPERIENCE

S. Fracchiolla, F. Guidotti, G. Reda, **N. Orofino**, C. Boschetti, M. Colombi, D. Vincenti, S. Guarco, E. Santambrogio, A. Cortelezzi

METABOLIC SYNDROME AND TKIS TREATMENT IN CHRONIC MYELOID LEUKEMIA

A. Iurlo, E. Orsi, C. Bucelli, **N. Orofino**, V. Resi, D. Zimbalatti, D. Cattaneo, D. Consonni, A. Cortelezzi

DIABETES MELLITUS AND TKIS TREATMENT IN CHRONIC MYELOID LEUKEMIA

A. Iurlo, E. Orsi, **N. Orofino**, D. Zimbalatti, D. Cattaneo, C. Bucelli, V. Resi, D. Consonni, A. Cortelezzi

OXIDATIVE STATUS IN ESSENTIAL THROMBOCYTHEMIA

A. Iurlo, R. De Giuseppe, D. Cattaneo, C. Bucelli, **N. Orofino**, P. Bianchi, C. De Vita, D. Consonni, U. Gianelli, F. Bamonti, A. Cortelezzi

56th ASH Annual Meeting and Exposition, San Francisco, CA, December, 2014

Spleen Stiffness Measurement By Transient Elastography As a Predictor of Bone Marrow Fibrosis in Primary Myelofibrosis Patients

A. Iurlo, D. Cattaneo, M. Giunta, U. Gianelli, G. Casazza, M. Fraquelli, **N. Orofino**, C. Bucelli, P. Bianchi, C. Augello, S. Bosari, M. Colombo, A. Cortelezzi

A 5-years Follow-up in Deferasirox Treatment: Improvement of Cardiac and Hepatic Iron Overload and Amelioration in Cardiac Function in Thalassemia Major Patients

E. Cassinerio, A. Roghi, **N. Orofino**, P. Pedrotti, L. Zanaboni, E. Poggiali, M. Giuditta, D. Consonni, MD. Cappellini

45° Congresso Nazionale Società Italiana di Ematologia, Firenze 4-7 ottobre 2015

(1-3)-b-D-GLUCAN DETERMINATION IN ONCO-HEMATOLOGIC PATIENTS AND ITS ROLE IN THERAPEUTIC STRATEGY: A PROSPECTIVE STUDY

N.S. Fracchiolla, F. Guidotti, A. Grancini, **N. Orofino**, C. Annaloro, G. Mometto, E. Torresani, A. Cortelezzi

PRIMARY HYPEREOSINOPHILIC SYNDROMES AND IMATINIB THERAPY: A RETROSPECTIVE

ANALYSIS OF 38 CASES

N. Orofino, D. Cattaneo, T. Intermesoli, O. Spinelli, G. Reda, U. Gianelli, A. Beghini, A. Rambaldi, A. Cortelezzi, A. Iurlo

CARDIOPULMONARY EXERCISE TESTING FOR EARLY DETECTION OF PULMONARY HYPERTENSION IN PRIMARY MYELOFIBROSIS

A. Iurlo, M. Sciumè, V. Mattiello, I. Cortinovis, **N. Orofino**, D. Cattaneo, A. Pierini, A. Cortelezzi

TYPE 1 VS TYPE 2 CALRETICULIN MUTATIONS AND THROMBOTIC RISK IN ESSENTIAL THROMBOCYTHEMIA PATIENTS: ANALYSIS OF A MONOCENTRIC SERIES

A. Iurlo, D. Cattaneo, S. Fabris, M. Sciumè, **N. Orofino**, F. Guidotti, G. Ciceri, D. Giannarelli, U. Gianelli, L. Gugliotta, A. Neri, A. Cortelezzi

57th ASH Annual Meeting and Exposition, Orlando, FL, December, 2015

Echocardiography and Cardiopulmonary Exercise Testing for Early Detection of Pulmonary Hypertension in Primary Myelofibrosis

Alessandra Iurlo, Mariarita Sciumè, Veronica Mattiello, Daniele Cattaneo, **Nicola Orofino**, Ivan Cortinovis, Umberto Gianelli, Alberto Pierini, and Agostino Cortelezzi

Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases

G. Reda, B. Fattizzo, R. Cassin, **N. Orofino**, E. Flospergher, A. Iurlo, W. Barcellini, A. Cortelezzi

Comprehensive Biological and Molecular Characterization of a Rare Case of Cutaneous Richter Syndrome

R. Cassin, G. Reda, S. Fabris, **N. Orofino**, B. Fattizzo, U. Gianelli, A. Neri, A. Cortelezzi

Peripherally Inserted central Catheters (PICCs) Implantation in the Clinical Management of Oncohematologic Patients: Results of a Large Multicenter, Retrospective Study of the REL group (Rete Ematologica Lombarda – Lombardy Hematologic Network, Italy)

NS. Fracchiolla, E. Todisco, A. Bilancia, S. Gandolfi, V. Mancini, L. Marbello, Bernardi M, Assanelli A, **N. Orofino**, R. Cassin, M. Sciumè, F. Guidotti, R. Cairoli, F. Ciceri, A. Santoro, A. Cortelezzi, G. Rossi

21th Congress of the European Hematology Association, Copenhagen, Denmark, June 2016

INFECTIOUS AND THROMBOTIC COMPLICATIONS IN PERIPHERALLY INSERTED (PICCS) COMPARED TO SHORT TERM CENTRAL VENOUS CATHETERS IN ONCOHEMATOLOGIC PATIENTS: A REL GROUP (RETE EMATOLOGICA LOMBARDA) STUDY

NS Fracchiolla, E Todisco, A Bilancia, S Gandolfi, V Mancini, L Marbello, M Bernardi, A Assanelli, **N Orofino**, F Guidotti, R Cairoli, F Ciceri, A Santoro, G Rossi, A Cortelezzi

SECONDARY MALIGNANCIES IN CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTRE RETROSPECTIVE ANALYSIS

G Reda, B Fattizzo, R Cassin, **N Orofino**, E Flospergher, D Consonni, W Barcellini, A Cortelezzi

58th ASH Annual Meeting and Exposition, San Diego, CA, December 2016

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Soverini S, DeBenedittis C, Stella S, Serra A, Carnuccio F, Errichiello S, Bavaro L, Castagnetti F, Iurlo A, **Orofino N**, Sorà F, Sica S, Galimberti S, Baratè C, Mottadelli C, Martelli M, Novella E, Di Bona E, Specchia G, Albano F, Abruzzese E, Ciceri F, Lunghi F, Fava C, Rege Cambrin G, Luciano L, Breccia M, Caracciolo C, Santoro M, Di Raimondo F, Gugliotta G, Papayannidis C, Cazzaniga G, Mancini M, Sancetta R, Bassan R, Musolino C, Spinosa G, Capalbo SF, Annunziata M, Cavo M, Rosti G, Baccarani M, Vigneri P, Saglio G, Pane F, Martinelli G.

How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)

Luigi Gugliotta, Alessandra Iurlo, Gabriele Gugliotta, Alessia Tieghi, Lucia Canafoglia, Raffaele Palmieri, Crescenza Pasciolla, Nicola Vianelli, Riccardo ragionieri, Erminia Rinaldi, Emilio Usala, Giorgio La Nasa, Alessandra Perra, Giuseppe Tagariello, Nilla Machio, Emma Cacciola, Rossella Rosaria Cacciola, Micaela Bergamaschi, Anna Da Col, Angela Rago, Lorenzo Rizzo, Francesco Spina, Daniele Cattaneo, Daniela Lambertenghi, Aniello Casoria, Maria Langella, Maria Luigia Rinaldi, Elisabetta Cusi, Monica Crugnola, Elena Masselli, Paola Ranalli, Giovanna Garozzo, Katia Codeluppi, Oreste Villani, Grazia Ferrara, Cristina Santoro, Potito Rosario Scalzulli, Manlio Ricciotti, Viviana Appolloni, Anna Candoni, Annalis Luraschi, Ruoli Serena, Mauro Di Ianni, Giovanni Caocci, Francesco Lanza, **Nicola Orofino**, Elisa Rumi, Alfredo Dragani, Bruno Martino, Anna Marina Liberati, Umberto Santoro and Alessandro M. Vannucchi.

22nd Congress of the European Hematology Association, Madrid, Spain, June 2017

ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY

Simona Soverini, Caterina De Benedittis, Luana Bavaro, Margherita Martelli, Stefania Stella, Alessandra Iurlo, **Nicola Orofino**, Claudia Baratè, Sara Galimberti, Simona Sica, Federica Sorà, Antonella Russo Rossi, Francesco Albano, Fabio Ciceri, Francesca Lunghi, Fausto Castagnetti, Gabriele Gugliotta, Elena Tenti, Gianantonio Rosti, Cristina Papayannidis, Fabio Stagno, Paolo Vigneri, Anna Serra, Giuseppe Saglio, Francesca Carnuccio, Fabrizio Pane, Santa Errichiello, Mario Annunziata, Massimo Breccia, Elisabetta Abruzzese, Massimiliano Bonifacio, Elisabetta Novella, Eros Di Bona, Rosaria Sancetta, Elisabetta Calistri, Giuseppina Spinosa, Mariella D'Adda, Isabella Capodanno, Michele Baccarani, Michele Cavo, Giovanni Martinelli

The grade of stromal changes impacts on prognosis in patients with primary myelobibrosis.

U. Gianelli, S. Fiori, D. Cattaneo, A. Bossi, I. Cortinovis, C. Bucelli, **N. Orofino**, A. Iurlo

46° Congresso Nazionale Società Italiana di Ematologia, Roma 15-18 ottobre 2017

PROGNOSTIC SIGNIFICANCE OF A COMPREHENSIVE HISTOLOGIC EVALUATION OF RETICULIN FIBROSIS, COLLAGEN DEPOSITION AND OSTEOSCLEROSIS IN PRIMARY MYELOFIBROSIS PATIENTS

U. Gianelli, S. Fiori, D. Cattaneo, A. Bossi, I. Cortinovis, A. Bonometti, G. Ercoli, C. Bucelli, **N. Orofino**, A. Iurlo

ESTABLISHING A NATIONAL NETWORK OF LABORATORIES PERFORMING BCR-ABL KINASE DOMAIN MUTATION SCREENING BY NEXT GENERATION AMPLICON DEEP SEQUENCING: RESULTS OF THE 'NEXT-IN-CML' STUDY

S. Soverini, C. De Benedittis, L. Bavaro, M. Martelli, S. Stella, A. Iurlo, **N. Orofino**, C. Baratè, S. Galimberti, S. Sica, F. Sorà, A. Russo Rossi, F. Albano, F. Ciceri, F. Lunghi, F. Castagnetti, G. Gugliotta, E. Tenti, G. Rosti, C. Papayannidis, F. Stagno, P. Vigneri, A. Serra, G. Saglio, F. Carnuccio, F. Pane, S. Errichiello, M. Annunziata, M. Breccia, E. Abruzzese, M. Bonifacio, E. Novella, E. Di Bona, R. Sancetta, E. Calistri, G. Spinosa, M. D'Adda, I. Capodanno, M. Bocchia, M. Salvucci, M. Baccarani, M. Cavo, G. Martinelli

AN UNUSUAL TYPE OF MYELOID SARCOMA LOCALIZATION FOLLOWING MYELOFIBROSIS

N. Orofino, D. Cattaneo, C. Bucelli, L. Pettine, S. Fabris, U. Gianelli, N.S. Fracchiolla, A. Iurlo

REACTIVE FOLLICULAR HYPERPLASIA DURING DASATINIB TREATMENT: AN UNDERESTIMATED ADVERSE EVENT

C. Bucelli, D. Cattaneo, **N. Orofino**, J.A. Giannotta, M. Zappa, L. Cro, U. Gianelli, A. Iurlo

59th ASH Annual Meeting and Exhibition, December 9-12, 2017

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

S. Soverini, L. Bavaro, C. DeBenedittis, M. Martelli, S. Stella, P. Vigneri, A. Iurlo, **N. Orofino**, S. Sica, F. Sorà, S. Galimberti, C. Baratè, F. Albano, A. Russo Rossi, F. Ciceri, F. Lunghi, F. Castagnetti, G. Gugliotta, G. Rosti, E. Tenti, F. Stagno, E. Novella, E. Di Bona, M. Bonifacio, E. Abbruzzese, M. Salvucci, M. D'Adda, R. Sancetta, E.

Calistri, M. Bocchia, I. Capodanno, G. Spinosa, MA. Laginestra, S. Errichiello, A. Serra, F. Carnuccio, S. Coluzzi, M. Annunziata, C. Musolino, F. Pane, G. Saglio, M. Baccarani, M. Cavo and G. Martinelli

Autorizzo il trattamento dei dati personali ai sensi dell'art. 13 del D. Lgs. 196/2003 e dell'art. 13 GDPR 679/16.

Data

31/03/2019

Luogo

Cernusco sul Naviglio (Mi)